Evidence guide · UK

NMN and NR for muscle loss with age: what the November 2026 review and the trials show

A GeroScience review indexed on 17 November 2026 concluded that NMN and nicotinamide riboside cannot be recommended routinely for sarcopenia. The pooled trials in adults with a mean age over 60, what each trial measured, and the rules in the UK, US, UAE and South Africa.

Review type: research summary. This page summarises published research and product labels, cited below.

Sarcopenia is the age-related loss of muscle strength, mass and function, and NAD+ precursors such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are marketed as a way to slow it. A review published in GeroScience and indexed on 17 November 2026 screened 1,763 records on nucleotides and NAD+ precursors in sarcopenia, kept 65 publications, and concluded that current evidence does not justify recommending NMN or NR routinely for sarcopenia. A 2025 pooled analysis of the human trials agrees.

Short answer: NR raised the NAD+ metabolome in whole blood and in muscle in one small trial. NMN raised NAD+ in blood cells in a prediabetes trial, but muscle NAD+ itself did not rise. In adults with a mean age over 60 they have not been shown to improve muscle mass, grip strength, walking speed or chair-stand tests. The NHS recommends strength activity for older adults, and this site's pages on creatine, protein per meal and resistance training cover the trial evidence for muscle. If you take NMN or NR anyway, do not expect a benefit for muscle mass, grip strength, walking speed or chair-stand time. One NR trial in peripheral artery disease did report a longer six-minute walk.

Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies, or good studies in other groups of people), Insufficient (too little human research to judge) and Evidence of harm.

What the November 2026 review concludes

Gdańska and colleagues searched PubMed, Scopus and Web of Science, identified 3,090 records, removed 1,327 duplicates, screened 1,763 and assessed 159 in full text. They retained 62 publications, and three additional clinical reports found during revision brought the synthesis to 65. It is a structured literature review, not a meta-analysis, so it does not produce a pooled effect size.

For conventional dietary nucleotides, the most direct evidence comes from cell and animal models plus several human intervention studies, which the authors say suggest potential to attenuate muscle atrophy and improve selected functional outcomes. For NAD+ precursors the evidence is considerably more extensive but the clinical findings are heterogeneous. The authors call nucleotides promising but experimental, and say current evidence does not justify treating mixtures of AMP, CMP, GMP and UMP, nucleoproteins, NMN and NR as equivalent interventions or recommending their routine use in sarcopenia.

The pooled trial data in older adults

Prokopidis and colleagues pooled randomised trials of NMN or NR against placebo in participants with mean ages from 60.9 to 83 years. For NMN, they found no significant effect on skeletal muscle index (3 trials, mean difference -0.42, 95% CI -0.99 to 0.14), handgrip strength (no significant effect in either of two analyses, because one trial reported the hands separately: 5 trials, mean difference 0.61 kg, 95% CI -0.89 to 2.10 when the left-hand value was added, and 0.45 kg, -1.06 to 1.96 when the right-hand value was added), gait speed (4 trials, -0.01, -0.08 to 0.06) or the five-times chair-stand test (2 trials, -0.21, -0.70 to 0.29). Narrative synthesis found no significant change from NMN in knee extension strength or the Short Physical Performance Battery. One included trial reported a significant reduction in thigh muscle mass with NMN versus placebo (p < 0.01).

For NR, the picture was mixed rather than clearly positive. NR was associated with a longer six-minute walking distance in people with peripheral artery disease, but lower Short Physical Performance Battery scores and slower chair stands in people with mild cognitive impairment. The authors conclude that current evidence does not support NMN and NR supplementation for preserving muscle mass and function in adults with a mean age over 60, and suggest future work on dose, baseline NAD+ deficiency and combinations with other interventions.

What individual trials show

A 24-week placebo-controlled trial gave 250 mg of NMN a day to 14 men with diabetes, mean age 81.1, who had reduced grip strength or walking speed. NMN was tolerable. Grip strength changed by 1.25 kg on NMN (95% CI -2.31 to 4.81) and -0.44 kg on placebo, and walking speed by 0.033 m/s on NMN (-0.021 to 0.087) and 0.014 m/s on placebo. The authors report no difference between groups. The confidence intervals are wide, so a modest difference is not ruled out.

A crossover trial in 12 older men gave 1 g of NR a day for 21 days. It raised the muscle NAD+ metabolome, which shows oral NR reaches aged human muscle, and lowered circulating inflammatory cytokines, but did not change muscle mitochondrial bioenergetics. One author is the inventor of patents licensed by ChromaDex, owns ChromaDex stock and advises the company.

A trial randomised 32 people aged 55 to 80 to 1,000 mg of NR plus 200 mg of pterostilbene a day or placebo. After two weeks, muscle injury was induced with electrically driven eccentric work. The supplement did not improve recruitment of muscle stem cells or the other measures of muscle recovery the trial assessed over the next 30 days. The authors report that the supplement was safe over that period. The study was funded by the Novo Nordisk Foundation. One author is employed by Elysium Health and has stock options.

One NMN trial in muscle measured a different outcome. A 10-week randomised trial in postmenopausal women with prediabetes who were overweight or obese reported that NMN increased insulin-stimulated glucose disposal and muscle insulin signalling, and raised expression of genes linked to muscle remodelling. The same trial measured handgrip strength, knee strength and fat-free mass, and none of those changed.

Why raising NAD+ may not help the muscle

A bibliometric and mechanistic review published on 6 November 2026 in Pharmacological Research analysed 3,271 NAD+ and ageing publications from 2004 to 2025. It reports that NAD+ production, use and balance differ by tissue and by compartment inside cells, so raising precursor levels in the body does not uniformly restore useful NAD+ in the tissue that needs it. It also finds that research on supplements such as NMN and NR has grown faster than clinical validation, and says that in sarcopenia, as in other conditions, NAD+ disturbances follow disease-specific mechanisms rather than one universal decline. This is an authors' interpretation, not a trial result.

Muscle mass and function in adults with a mean age over 60: Limited

Taken together, the trials that exist are small and short, and none shows a benefit on mass, grip strength or walking speed. The 2025 pooled analysis gives wide intervals that include both no effect and modest effects, so benefit is not ruled out, but nothing supports it either. That is Limited for NMN and NR on muscle function in older adults, and Limited for dietary nucleotide mixtures. The review cites several human intervention studies as well as cell and animal work, and still calls the nucleotides experimental.

What has evidence for muscle ageing

The NHS advises adults aged 65 and over to do activities that improve strength, balance and flexibility on at least two days a week and to be physically active every day. This site's pages on creatine, protein per meal and resistance training during GLP-1 treatment cover the interventions with trial evidence for muscle. Weakness, falls or unintended weight loss in an older adult are reasons to see a doctor, not to start a supplement.

Our view

  • Do not buy NMN or NR to protect your muscles. The pooled trials, in adults with a mean age over 60, show no significant benefit for muscle mass, grip strength or walking speed.
  • If you already take either, a lack of change in strength is the expected result, so do not rely on it in place of strength training and enough protein.
  • Read marketing that cites "NAD+ levels rose" as a blood or tissue measurement, not a muscle outcome. The 2019 NR trial shows the NAD+ metabolome rises in muscle, and hand-grip did not change in that trial. Later trials did not show a benefit for grip strength, gait speed or chair-stand time, although NR was associated with a longer six-minute walk in peripheral artery disease.
  • Treat dietary nucleotide blends as experimental. The review's most direct evidence includes cell and animal work and several human intervention studies, and it does not support routine use.
  • If an older relative is losing strength, ask a doctor to check for causes and arrange strength training before considering a supplement.

UK rules

Food supplements in the UK are regulated as food, are not medicinal products and are not intended to treat or prevent disease, so a claim that an NAD+ product treats or prevents sarcopenia has no place on a label or advert. The NHS recommends strength activity for adults aged 65 and over. Tell your GP or pharmacist before adding an NMN or NR product if you take regular medicines, and report suspected side effects of a medicine through the MHRA Yellow Card scheme.

FAQ

Does NMN help muscle loss with age?

Not on current evidence. A 2025 pooled analysis of randomised trials in people with a mean age over 60 found no significant effect of NMN on skeletal muscle index, grip strength, gait speed or chair-stand time, and a November 2026 review concluded that NMN and NR cannot be recommended routinely for sarcopenia.

Does nicotinamide riboside build muscle?

No trial included here shows that it does. In a 21-day trial it raised NAD+ metabolites in older men's muscle without changing mitochondrial function, and in a trial of injury recovery it did not improve muscle regeneration. Results in other groups were mixed.

Are NAD+ precursors safe for older adults?

The trials above reported NMN at 250 mg a day for 24 weeks and NR at 1 g a day for 21 days as tolerable, in small groups. That does not establish long-term safety, particularly alongside other medicines, so ask a pharmacist or doctor first.

What works for sarcopenia?

Strength training is the intervention with consistent evidence, and the NHS recommends strength activities at least two days a week for adults aged 65 and over. A doctor can look for causes of weakness and advise on protein and other treatment.

Sources

These are the documents this page relies on.

  1. Gdańska A, Karaś R, Binduga UE, Szychowski KA. Dietary nucleotides and NAD+ precursors in age-related sarcopenia. GeroScience. 2026 (indexed in PubMed 17 November 2026). doi:10.1007/s11357-026-02659-0GeroScience (PubMed 43040062)
  2. Prokopidis K, Moriarty F, Bahat G, McLean J, Church DD, Patel HP. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2025;16(3):e13799Journal of Cachexia, Sarcopenia and Muscle (PubMed 40275690)
  3. Akasaka H, Nakagami H, Sugimoto K, et al. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: a prospective, placebo-controlled, double-blind study. Geriatr Gerontol Int. 2023;23(1):38-43Geriatrics and Gerontology International (PubMed 36443648)
  4. Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Rep. 2019;28(7):1717-1728Cell Reports (PubMed 31412242)
  5. Jensen JB, Dollerup OL, Møller AB, et al. A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals. JCI Insight. 2022;7(19):e158314JCI Insight (PubMed 35998039)
  6. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229Science (PubMed 33888596)
  7. Pei Z, Zhong M, Jiang Q, et al. From NAD+ elevation to clinical benefit: tissue-specific regulation and translational barriers in aging and age-related disease. Pharmacol Res. 2026;234:109743Pharmacological Research (PubMed 42994542)
  8. Physical activity guidelines for older adultsNHS
  9. Food supplements: guidance for businessesGOV.UK
  10. Yellow Card: report a side effectMedicines and Healthcare products Regulatory Agency